Alexion Pharmaceuticals Inc (ALXN)

97.70
0.80 0.81
NASDAQ : Health Care
Prev Close 98.50
Open 98.77
Day Low/High 96.18 / 99.44
52 Wk Low/High 110.56 / 205.29
Volume 6.66M
Avg Volume 2.40M
Exchange NASDAQ
Shares Outstanding 224.56M
Market Cap 22.12B
EPS 1.80
P/E Ratio 46.90
Div & Yield N.A. (N.A)

Latest News

Trader's Daily Notebook: As Long Weekend Nears, Volume Will Stay Low

Trader's Daily Notebook: As Long Weekend Nears, Volume Will Stay Low

If you want to stay active, you'll have to do more homework.

Alexion Shares Drop Amid Executive Changes

Alexion Shares Drop Amid Executive Changes

The biopharmaceutical firm on Tuesday announced changes, including the planned departure of its chief financial officer.

BMO: Too Early to Tell If Alexion's Management Shakeup Bodes Well for Stock

BMO: Too Early to Tell If Alexion's Management Shakeup Bodes Well for Stock

The biopharmaceutical firm's CFO announced today that he will be leaving in August.

Biotech Movers: Cerus, Alexion, NantKwest

Biotech Movers: Cerus, Alexion, NantKwest

Cerus, Alexion Pharmaceuticals and NantKwest were among the biotech movers in premarket trading on Tuesday.

Alexion Announces Executive Leadership Changes

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced the following changes to its executive leadership team: Brian Goff is joining Alexion as Chief Commercial Officer, effective June 1, 2017.

Walgreens Boots Alliance, Becton Dickinson, General Mills: 'Mad Money' Lightning Round

Walgreens Boots Alliance, Becton Dickinson, General Mills: 'Mad Money' Lightning Round

Jim Cramer is bullish on Walgreens Boots Alliance, Becton Dickinson, and General Mills.

Going for the Growth: Cramer's 'Mad Money' Recap (Thursday 5/18/17)

Going for the Growth: Cramer's 'Mad Money' Recap (Thursday 5/18/17)

Money managers are piling back into growth stocks without hesitation, says Jim Cramer.

(Graphic: Business Wire)

The Rady Children's Institute for Genomic Medicine (RCIGM) and Alexion Pharmaceuticals, Inc.

Long-term Data Confirm Benefits Of Treatment With Strensiq® (asfotase Alfa) In Adolescents And Adults With Hypophosphatasia (HPP) Through Five Years

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today that researchers presented data showing that the rapid benefits of Strensiq® (asfotase alfa) achieved in adolescents and adults (ages 13-66 years at study...

Alexion Global Headquarters Earns Highest LEED® Green Building Certification

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and The Connecticut Green Building Council (CTGBC) today announced that Alexion's global headquarters at 100 College Street in New Haven has achieved LEED Platinum certification...

Alexion To Present At The Bank Of America Merrill Lynch 2017 Health Care Conference

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the Bank of America Merrill Lynch 2017 Health Care Conference in Las Vegas on Tuesday, May 16, 2017 at 10:40 a.

Brazilian Police Raid Alexion Offices in Sales Probe

Brazilian Police Raid Alexion Offices in Sales Probe

Alexion said that the officers have left and the company is cooperating with the investigation.

Alexion Pharmaceuticals Moves Up In Analyst Rankings, Passing EOG Resources

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Alexion Pharmaceuticals Inc. has taken over the #108 spot from EOG Resources, Inc.

Alexion Rises More Than 5% After Beating Consensus

Alexion Rises More Than 5% After Beating Consensus

Soliris sales of $783 million in the first quarter benefited from a one-time, $29 million change in revenue recognition but still came in higher than consensus.

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

Biotech Movers: Pacific Biosciences Falls After Net Loss Spikes

Biotech Movers: Pacific Biosciences Falls After Net Loss Spikes

Pacific Biosciences of California, Alexion Pharmaceuticals and Arena Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

Alexion Reports First Quarter 2017 Results

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the first quarter of 2017.

Johnson & Johnson's Weak Pharma Revenue Could Spell Doom for Rest of Sector

Johnson & Johnson's Weak Pharma Revenue Could Spell Doom for Rest of Sector

The New Brunswick, N.J.-based company noted that its pharma sales dipped due to weakness in the U.S. compared to other markets.

Alexion To Report First Quarter 2017 Results On Thursday, April 27, 2017

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the first quarter ended March 31, 2017 on Thursday, April 27, 2017 before the US financial markets open.

Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market

Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market

The pharmaceutical giant has an attractive yield supported by double-digit earnings growth.

Alexion Pharma, Still Recovering From Boardroom Troubles, Appoints New CEO

Alexion Pharma, Still Recovering From Boardroom Troubles, Appoints New CEO

Ludwig Hantson takes over the top Alexion job after serving as CEO of Baxalta, which he helped sell to Shire for $32 billion.

Ludwig N. Hantson, Ph.D. (Photo: Business Wire)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that its Board of Directors has appointed Ludwig N.

Biotech Premarket Movers: Insys, Ultragenyx, Alexion

Biotech Premarket Movers: Insys, Ultragenyx, Alexion

Insys Therapeutics, Ultragenyx Pharmaceutical and Alexion Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.

Alexion Submits Application In Japan For Soliris® (Eculizumab) As A Potential Treatment For Patients With Refractory Generalized Myasthenia Gravis (gMG)

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today that it has submitted an application to Japan's Ministry of Labour and Welfare (MHLW) to extend the indication for Soliris ® (eculizumab) as a potential...

Alexion Pharmaceuticals Cuts 7% of Workforce

Alexion Pharmaceuticals Cuts 7% of Workforce

Alexion Pharmaceuticals is restructuring its business.